Research and Development Arrangements and Related Party Transactions (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Research and Development Arrangements and Related Party Transactions | ||||
| Research and development | $ 1,101,000 | $ 2,291,000 | $ 6,013,000 | $ 4,797,000 |
| Related Party | ChemDiv | ||||
| Research and Development Arrangements and Related Party Transactions | ||||
| Research and development | 653,000 | $ 1,294,000 | 2,027,000 | $ 2,300,000 |
| Related Party | ChemDiv | Accounts Payable | ||||
| Research and Development Arrangements and Related Party Transactions | ||||
| Research and development payable | $ 1,856,000 | $ 1,856,000 | ||
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|